ストックスクリーナーアプリを入手
2.04
3.03%
0.06
前日終値:
$1.98
開ける：
$2
24時間の取引高:
587.89K
Relative Volume:
0.59
時価総額：
$252.01M
収益：
$36.86M
当期純損益:
$-171.67M
株価収益率:
-1.00
EPS:
-2.04
ネットキャッシュフロー:
$-171.05M
1週間 パフォーマンス:
-7.69%
1か月 パフォーマンス:
-0.49%
6か月 パフォーマンス:
-20.62%
1年 パフォーマンス:
+36.45%
1日の値動き範囲:
$1.9507
$2.115
1週間の範囲:
$1.9507
$2.35
52週間の値動き範囲:
$1.22
$6.2801
Mersana Therapeutics Inc Stock (MRSN) Company Profile
MRSN を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
| MRSN | 2.04 | 252.01M | 36.86M | -171.67M | -171.05M | -2.04 |
| VRTX | 450.97 | 116.14B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 738.00 | 81.10B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 605.92 | 36.23B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 244.89 | 31.59B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 113.13 | 27.12B | 3.30B | -501.07M | 1.03B | 11.54 |
Mersana Therapeutics Inc Stock (MRSN) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2023-12-04 | アップグレード | Citigroup | Neutral → Buy |
| 2023-07-28 | ダウングレード | Robert W. Baird | Outperform → Neutral |
| 2023-07-27 | ダウングレード | BTIG Research | Buy → Neutral |
| 2023-07-27 | ダウングレード | Citigroup | Buy → Neutral |
| 2023-07-27 | ダウングレード | Guggenheim | Buy → Neutral |
| 2023-07-27 | ダウングレード | JP Morgan | Neutral → Underweight |
| 2023-07-27 | ダウングレード | Truist | Buy → Hold |
| 2023-07-27 | ダウングレード | Wedbush | Outperform → Neutral |
| 2023-06-16 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2023-06-15 | 開始されました | Guggenheim | Buy |
| 2023-03-16 | アップグレード | JP Morgan | Neutral → Overweight |
| 2023-01-20 | 開始されました | Citigroup | Buy |
| 2022-11-21 | 開始されました | Truist | Buy |
| 2021-10-15 | 再開されました | BTIG Research | Buy |
| 2021-08-30 | 開始されました | H.C. Wainwright | Buy |
| 2021-03-31 | 開始されました | Credit Suisse | Neutral |
| 2020-12-03 | 開始されました | Stifel | Buy |
| 2020-09-29 | 再開されました | JP Morgan | Neutral |
| 2020-04-29 | 開始されました | BTIG Research | Buy |
| 2020-01-21 | 繰り返されました | H.C. Wainwright | Buy |
| 2019-03-11 | ダウングレード | JP Morgan | Neutral → Underweight |
| 2018-11-14 | アップグレード | Leerink Partners | Mkt Perform → Outperform |
| 2018-05-08 | 開始されました | Robert W. Baird | Outperform |
| 2018-03-19 | ダウングレード | JP Morgan | Overweight → Neutral |
すべてを表示
Mersana Therapeutics Inc (MRSN) 最新ニュース
This Particular Biotech Stock Is Soaring On Two Key Announcements - MSN
Mersana Therapeutics (STU:0M4) Cyclically Adjusted Revenue per Share : €0.00 (As of Sep. 2024) - GuruFocus.com
Mersana Therapeutics Q3 2024 Earnings Preview - MSN
16,178 Shares in Mersana Therapeutics, Inc. (NASDAQ:MRSN) Acquired by US Bancorp DE - Defense World
Leerink Partnrs Issues Optimistic Estimate for MRSN Earnings - Defense World
Wedbush Predicts Stronger Earnings for Mersana Therapeutics - Defense World
Wedbush Expects Increased Earnings for Mersana Therapeutics - MarketBeat
FY2024 Earnings Estimate for MRSN Issued By Leerink Partnrs - MarketBeat
Mersana Therapeutics transferred with Buy rating at Citi - MSN
MRSN (Mersana Therapeutics) Short-Term Capital Lease Obliga - GuruFocus.com
Citi bullish on mersana stock ahead of XMT-1660 data catalyst - Investing.com
Mersana Therapeutics (NASDAQ:MRSN) Coverage Initiated at Citigroup - MarketBeat
MRSN (Mersana Therapeutics) Short-Term Debt : $8.33 Mil (As of Jun. 2024) - GuruFocus.com
MRSN (Mersana Therapeutics) Purchase Of Business : $0.00 Mil (TTM As of Jun. 2024) - GuruFocus.com
MRSN (Mersana Therapeutics) ROE % Adjusted to Book Value : -18.30% (As of Jun. 2024) - GuruFocus.com
MRSN (Mersana Therapeutics) Debt-to-Revenue : 3.52 (As of Jun. 2024) - GuruFocus.com
MRSN (Mersana Therapeutics) Change In Receivables : $-1.57 Mil (TTM As of Jun. 2024) - GuruFocus.com
MRSN (Mersana Therapeutics) Change In Prepaid Assets : $5.85 Mil (TTM As of Jun. 2024) - GuruFocus.com
MRSN (Mersana Therapeutics) Retained Earnings : $-869.94 Mil (As of Jun. 2024) - GuruFocus.com
Mersana Therapeutics Provides Business Update and Financial Results for Third Quarter 2024 - Defense World
MRSN (Mersana Therapeutics) Ending Cash Position : $59.48 Mil (As of Jun. 2024) - GuruFocus.com
Earnings call: Mersana Therapeutics reports progress in ADC clinical trials By Investing.com - Investing.com Nigeria
MRSN (Mersana Therapeutics) Free Cash Flow : $-95.57 Mil (TTM As of Sep. 2024) - GuruFocus.com
MRSN (Mersana Therapeutics) Capex-to-Operating-Cash-Flow : 0.00 (As of Jun. 2024) - GuruFocus.com
MRSN (Mersana Therapeutics) Cash Flow for Lease Financing : $0.00 Mil (TTM As of Jun. 2024) - GuruFocus.com
MRSN (Mersana Therapeutics) Other Long-Term Liabilities : $0.02 Mil (As of Sep. 2024) - GuruFocus.com
MRSN (Mersana Therapeutics) Long-Term Capital Lease Obligat - GuruFocus.com
MRSN (Mersana Therapeutics) Effect of Exchange Rate Changes : $0.00 Mil (TTM As of Jun. 2024) - GuruFocus.com
MRSN (Mersana Therapeutics) Other Stockholders Equity : $-0.00 Mil (As of Jun. 2024) - GuruFocus.com
MRSN (Mersana Therapeutics) Issuance of Debt : $0.00 Mil (TTM As of Jun. 2024) - GuruFocus.com
MRSN (Mersana Therapeutics) Net Income From Continuing Operations : $-104.77 Mil (TTM As of Jun. 2024) - GuruFocus.com
MRSN (Mersana Therapeutics) Cash Flow from Operations : $-132.56 Mil (TTM As of Jun. 2024) - GuruFocus.com
Earnings call: Mersana Therapeutics reports progress in ADC clinical trials - Investing.com
Balyasny Asset Management L.P. Acquires New Stake in Mersana The - GuruFocus.com
Mersana Therapeutics, Inc. (NASDAQ:MRSN) Q3 2024 Earnings Call Transcript - Insider Monkey
Rivian, Mersana Therapeutics, MicroStrategy (MSTR) and Honest Company Among Strong Movers in Premarket Trades - TopNews India
Mersana Therapeutics Inc (MRSN) Q3 2024 Earnings Call Highlights: Strategic Advances and ... - Yahoo Finance
Mersana Therapeutics Reports Q3 2024 Financial Results - TipRanks
Dow Jones Industrials Average (DOWI) QuotePress Release - The Globe and Mail
FANG Index (FGU25) Quote - The Globe and Mail
Mersana Therapeutics Shares Climb 23% After 3Q Results Beat Estimates - MarketWatch
Mersana Therapeutics, Inc. (MRSN) Reports Q3 Loss, Tops Revenue Estimates - Yahoo Finance
Mersana Therapeutics (MRSN) Q3 2024 Earnings: EPS Loss of $0.09 Beats Estimates, Revenue Surges to $12.6M - GuruFocus.com
Mersana Therapeutics Reports Progress in Cancer Treatments - TipRanks
Mersana Therapeutics Provides Business Update and Announces Third Quarter 2024 Financial Results - GlobeNewswire
Mersana Therapeutics, Inc. Provides Business Update - Marketscreener.com
Earnings Preview For Mersana Therapeutics - Benzinga
Mersana Therapeutics presents new data on XMT-2056 - BioWorld Online
Mersana Therapeutics, Inc. (NASDAQ:MRSN) Receives $6.00 Consensus Price Target from Brokerages - Defense World
Is Mersana Therapeutics (NASDAQ:MRSN) Using Debt Sensibly? - Simply Wall St
Brokerages Set Mersana Therapeutics, Inc. (NASDAQ:MRSN) Target Price at $6.00 - MarketBeat
Mersana Therapeutics Inc (MRSN) 財務データ
収益
当期純利益
現金流量
EPS
1.89%
2.08%
大文字化:
|
ボリューム (24 時間):